---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-029326"
form_type: "8-K"
ticker: "NRXS"
cik: "0001933567"
company_name: "Neuraxis, INC"
filed_at: "2023-08-17T23:59:59+00:00"
generated_at: "2026-06-11T08:03:48.140069+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NeurAxis reports over $8M in cumulative IB-Stim revenue through March 31, 2023

## Summary
- Over $8M in revenue from IB-Stim since commercial launch after FDA clearance for pediatric functional abdominal pain and IBS.
- Approximately $2M of total revenue was generated in 2019 and 2020.
- Company is conducting clinical trials for four additional pediatric indications: chronic nausea, post-concussion syndrome, chemo-induced nausea, and cyclic vomiting.
- CEO Brian Carrico cites growing adoption, non-drug therapy trend, and recently completed IPO funding.

## SEC filing metadata
- accession: 0001493152-23-029326
- form_type: 8-K
- ticker: NRXS
- cik: 0001933567
- company_name: Neuraxis, INC
- filed_at: 2023-08-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1933567/000149315223029326/0001493152-23-029326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1933567/000149315223029326/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-029326
- JSON: https://secwatch.observer/filing/0001493152-23-029326.json
- Plain text: https://secwatch.observer/filing/0001493152-23-029326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.